cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-2539cardiovascular-2539Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESКоморбидность хронической обструктивной болезни легких и сердечно-сосудистых заболеванийComorbidity in chronic obstructive pulmonary disease and cardiovascular diseasehttps://orcid.org/0000-0002-2712-0227ЧаулинА. М.ChaulinA. M.

Чаулин Алексей Михайлович — врач клинической лабораторной диагностики клинико-диагностической лаборатории, ассистент кафедры гистологии и эмбриологии.

Самара.

Chaulin Aleksey Michailovich.

Samara.

alekseymichailovich22976@gmail.comhttps://orcid.org/0000-0002-6453-2976ДупляковД. В.DuplyakovD. V.

Дупляков Дмитрий Викторович — доктор медицинских наук, заместитель главного врача по медицинской части, профессор кафедры кардиологии и сердечно-сосудистой хирургии Института профессионального образования.

Самара.

Duplyakov Dmitry Victorovich.

Samara.

duplyakov@yahoo.comСамарский областной клинический кардиологический диспансер; Самарский государственный медицинский университет Минздрава РоссииSamara Regional Clinical Cardiology Dispensary; Samara State Medical University20211102202120325392539Copyright © Чаулин А.М., Дупляков Д.В., 20212021Чаулин А.М., Дупляков Д.В.Chaulin A.M., Duplyakov D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2539

Коморбидность — одна из самых значимых проблем современного здравоохранения. В многочисленных исследованиях анализируются возможные патогенетические механизмы и взаимосвязи между самыми различными заболеваниями. Сердечно-сосудистые (ССЗ) и бронхолегочные заболевания, в частности хроническая обструктивная болезнь легких (ХОБЛ), имеют целый ряд одинаковых факторов риска и патогенетических звеньев, посредством которых утяжеляют течение друг друга. Более того, ССЗ и ХОБЛ являются одними из самых распространенных заболеваний в мире. В настоящем обзоре приводятся современные сведения о распространенности, факторах риска и патофизиологических механизмах, лежащих в основе данного неблагоприятного сочетания болезней. Также обсуждаются некоторые проблемы диагностики и лечения коморбидных пациентов, страдающих ХОБЛ и ССЗ.

Comorbidity is one of the most significant problems of modern healthcare. Numerous studies have analyzed the possible pathogenetic mechanisms and relationships between a wide variety of diseases. Cardiovascular (CVD) and pulmonary diseases, in particular chronic obstructive pulmonary disease (COPD), have a number of the same risk factors and pathogenetic links, which aggravate each other's course. Moreover, CVD and COPD are among the most common diseases in the world. This review provides up-to-date information on the prevalence, risk factors and pathophysiological mechanisms underlying this unfavorable combination of diseases. Some problems of diagnosis and treatment of patients with COPD and CVD are also discussed.

кардиоваскулярные заболеванияхроническая обструктивная болезнь легкихфакторы рискакурениевоспалениеокислительный стресспожилой возрастпатофизиологиядиагностикаcardiovascular diseaseschronic obstructive pulmonary diseaserisk factorssmokinginflammationoxidative stressold agepathophysiologydiagnosticsReferencesТарловская Е.И. Коморбидность и полиморбидность — современная трактовка и насущные задачи, стоящие перед терапевтическим сообществом. Кардиология. 2018;58(S9):29-38. doi:10.18087/cardio.2562.Tarlovskaya EI. Comorbidity and polymorbidity — a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiia. 2018;58(9S):29-38. (In Russ.)Верткин А. Л. Коморбидность: история, современное представление, профилактика и лечение. Кардиоваскулярная терапия и профилактика. 2015;14(2):74-9. doi:10.15829/1728-8800-2015-2-74-79.Vertkin AL. Comorbidity: history, recent views, prevention and treatment. Cardiovascular Therapy and Prevention. 2015;14(2):74-9. (In Russ.)Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05-020415.Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05-020415.GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706. doi:10.1016/S2213-2600(17)30293-X.GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706. doi:10.1016/S2213-2600(17)30293-X.Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-9. doi:10.1016/S2213-2600(15)00241-6.Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-9. doi:10.1016/S2213-2600(15)00241-6.Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015;3(8):593-5. doi:10.1016/S2213-2600(15)00279-9.Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015;3(8):593-5. doi:10.1016/S2213-2600(15)00279-9.Roversi S, Fabbri LM, Sin DD, et al. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am J Respir Crit Care Med. 2016;194(11):1319-36. doi:10.1164/rccm.201604-0690SO.Roversi S, Fabbri LM, Sin DD, et al. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am J Respir Crit Care Med. 2016;194(11):1319-36. doi:10.1164/rccm.201604-0690SO.Григорьева Н. Ю., Майорова М. В., Королёва М. Е., Самолюк М. О. Особенности формирования и развития сердечно-сосудистых заболеваний у больных хронической обструктивной болезнью легких. Терапевтический архив. 2019;91(1):16-47. doi:10.26442/00403660.2019.01.000027.Grigoryeva NYu, Maiorova IV, Korolyova ME, Samolyuk MO. Comorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Therapeutic Archive. 2019;91(1):16-47. (In Russ.)Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 2015;109(11):1371-80. doi:10.1016/j.rmed.2015.07.014.Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 2015;109(11):1371-80. doi:10.1016/j.rmed.2015.07.014.Morgan AD, Sharma C, Rothnie KJ, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann Am Thorac Soc. 2017;14(5):754-65. doi:10.1513/AnnalsATS.201611-932SR.Morgan AD, Sharma C, Rothnie KJ, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann Am Thorac Soc. 2017;14(5):754-65. doi:10.1513/AnnalsATS.201611-932SR.Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017;195(2):189-97. doi:10.1164/rccm.201602-0354OC.Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017;195(2):189-97. doi:10.1164/rccm.201602-0354OC.Decramer M, Janssens W. Chronic obstructive pulmonary disease and Comorbidities. Lancet Respir Med. 2013;1(1):73-83. doi:10.1016/S2213-2600(12)70060-7.Decramer M, Janssens W. Chronic obstructive pulmonary disease and Comorbidities. Lancet Respir Med. 2013;1(1):73-83. doi:10.1016/S2213-2600(12)70060-7.Fabbri LM. Smoking, Not COPD, as the Disease. N Engl J Med. 2016;374(19):1885-6. doi:10.1056/NEJMe1515508.Fabbri LM. Smoking, Not COPD, as the Disease. N Engl J Med. 2016;374(19):1885-6. doi:10.1056/NEJMe1515508.Rothnie KJ, Smeeth L, Herrett E, et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015;101(14):1103-10. doi:10.1136/heartjnl-2014-307251.Rothnie KJ, Smeeth L, Herrett E, et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015;101(14):1103-10. doi:10.1136/heartjnl-2014-307251.Freixa X, Portillo K, Pare C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission [published correction appears in Eur Respir J. 2015;46(5):1533]. Eur Respir J. 2013;41(4):784-91. doi:10.1183/09031936.00222511.Freixa X, Portillo K, Pare C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission [published correction appears in Eur Respir J. 2015;46(5):1533]. Eur Respir J. 2013;41(4):784-91. doi:10.1183/09031936.00222511.Беленков Ю. Н., Цветкова О. А., Привалова Е. В. и др. Коморбидность хронической обструктивной болезни легких и сердечно-сосудистых заболеваний: место терапии современными в-адреноблокаторами. Кардиология. 2019;59(6):48-55. doi:10.18087/cardio.2019.6.n458.Belenkov YN, Tsvetkova OA, Privalova EV, et al. Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern в-Adrenoblockers. Kardiologiia. 2019;59(6):48-55. (In Russ.)Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-21. doi:10.1378/chest.125.6.2309.Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-21. doi:10.1378/chest.125.6.2309.Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175-85. doi:10.1001/jamainternmed.2013.1016.Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175-85. doi:10.1001/jamainternmed.2013.1016.Майорова М.В., Григорьева Н.Ю., Кузнецов А.Н. Особенности ведения больных с хронической обструктивной болезнью легких, имеющих различные нарушения ритма. Медицинский альманах. 2018;1:101-5. doi:10.21145/2499-9954-2018-1-101-105.Mayorova MV, Grigoryeva NYu, Kuznetsov AN. Features of management of patients with chronic obstructive pulmonary disease having various rhythm disturbances. Medical Almanac. 2018;1:101-5. (In Russ.)Barnes PJ. Senescence in COPD and Its Comorbidities. Annu Rev Physiol. 2017;79:517-39. doi:10.1146/annurev-physiol-022516-034314.Barnes PJ. Senescence in COPD and Its Comorbidities. Annu Rev Physiol. 2017;79:517-39. doi:10.1146/annurev-physiol-022516-034314.Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(7):566-71. doi:10.1164/rccm.200809-1398OC.Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(7):566-71. doi:10.1164/rccm.200809-1398OC.Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012;67(7):606-12. doi:10.1136/thoraxjnl-2011-200949.Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012;67(7):606-12. doi:10.1136/thoraxjnl-2011-200949.Austin V, Crack PJ, Bozinovski S, et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond). 2016;130(13):1039-50. doi:10.1042/CS20160043.Austin V, Crack PJ, Bozinovski S, et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond). 2016;130(13):1039-50. doi:10.1042/CS20160043.Zhang W, Huang Q, Zeng Z, et al. Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells. Oxid Med Cell Longev. 2017;2017:7543973. doi:10.1155/2017/7543973.Zhang W, Huang Q, Zeng Z, et al. Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells. Oxid Med Cell Longev. 2017;2017:7543973. doi:10.1155/2017/7543973.Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. doi:10.1016/j.jacc.2013.02.092.Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. doi:10.1016/j.jacc.2013.02.092.Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574-80. doi:10.1136/thx.2003.019588.Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574-80. doi:10.1136/thx.2003.019588.Roversi S, Roversi P, Spadafora G, et al. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014;44(1):93-102. doi:10.1111/eci.12181.Roversi S, Roversi P, Spadafora G, et al. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014;44(1):93-102. doi:10.1111/eci.12181.Dockery DW, Evans JS. Tallying the bills of mortality from air pollution. Lancet. 2017;389(10082):1862-4. doi:10.1016/S0140-6736(17)30884-X.Dockery DW, Evans JS. Tallying the bills of mortality from air pollution. Lancet. 2017;389(10082):1862-4. doi:10.1016/S0140-6736(17)30884-X.Seidel D, Cheung A, Suh ES, et al. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2012;16(8):1015-9. doi:10.5588/ijtld.12.0050.Seidel D, Cheung A, Suh ES, et al. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2012;16(8):1015-9. doi:10.5588/ijtld.12.0050.Avdeev SN. Pulmonary hyperinflation in patients with COPD. Atmosphere. Pulmonology and Allergology. 2006;2:11-6. (In Russ.) Авдеев С.Н. Легочная гиперинфляция у больных ХОБЛ. Атмосфера. Пульмонология и Аллергология. 2006;2:11-6.Avdeev SN. Pulmonary hyperinflation in patients with COPD. Atmosphere. Pulmonology and Allergology. 2006;2:11-6. (In Russ.)Katajisto M, Kupiainen H, Rantanen P, et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int J Chron Obstruct Pulmon Dis. 2012;7:743-55. doi:10.2147/COPD.S35497.Katajisto M, Kupiainen H, Rantanen P, et al. Physical inactivity in COPD and increased patient perception of dyspnea. Int J Chron Obstruct Pulmon Dis. 2012;7:743-55. doi:10.2147/COPD.S35497.Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109-24. doi:10.1007/bf00175982.Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109-24. doi:10.1007/bf00175982.Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324(22):1539-47. doi:10.1056/NEJM199105303242203.Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324(22):1539-47. doi:10.1056/NEJM199105303242203.Chen R, Lin L, Tian JW, et al. Predictors of dynamic hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease patients. J Thorac Dis. 2015;7(7):1142-50. doi:10.3978/j.issn.2072-1439.2015.07.08.Chen R, Lin L, Tian JW, et al. Predictors of dynamic hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease patients. J Thorac Dis. 2015;7(7):1142-50. doi:10.3978/j.issn.2072-1439.2015.07.08.Dzeranova NYa, Isakov VA, Sizov AV. Chronic obstructive pulmonary disease. St. Petersburg.: SPbGPMU, 2018. p. 76. (In Russ.) Дзеранова Н. Я., Исаков В.А., Сизов А. В. Хроническая обструктивная болезнь легких. С.-Пб.: СПбГМУ, 2018. с. 76. ISBN: 978-5-907065-09-3.Dzeranova NYa, Isakov VA, Sizov AV. Chronic obstructive pulmonary disease. St. Petersburg.: SPbGPMU, 2018. p. 76. (In Russ.) Дзеранова Н. Я., Исаков В.А., Сизов А. В. Хроническая обструктивная болезнь легких. С.-Пб.: СПбГМУ, 2018. с. 76. ISBN: 978-5-907065-09-3.Zangiabadi A, De Pasquale CG, Sajkov D. Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int. 2014;2014:739674. doi:10.1155/2014/739674.Zangiabadi A, De Pasquale CG, Sajkov D. Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int. 2014;2014:739674. doi:10.1155/2014/739674.Podowski M, Calvi C, Metzger S, et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122(1):229-40. doi:10.1172/JCI46215.Podowski M, Calvi C, Metzger S, et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122(1):229-40. doi:10.1172/JCI46215.Chaudary N, Geraci SA. Prognostic value of cardiacspecific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J Miss State Med Assoc. 2014;55(2):40-4.Chaudary N, Geraci SA. Prognostic value of cardiacspecific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J Miss State Med Assoc. 2014;55(2):40-4.Чаулин А. М., Карслян Л. С., Григорьева Е. В. и др. Клинико-диагностическая ценность кардиомаркеров в биологических жидкостях человека. Кардиология. 2019;59(11):66-75. doi:10.18087/cardio.2019.11.n414.Chaulin AM, Karslyan LS, Bazyuk EV, et al. Clinical and Diagnostic Value of Cardiac Markers in Human Biological Fluids. Kardiologiia. 2019;59(11):66-75. (In Russ.)Waschki B, Alter P, Zeller T, et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study. Eur Respir J. 2019;55(2): pii: 1901314. doi:10.1183/13993003.01314-2019.Waschki B, Alter P, Zeller T, et al. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study. Eur Respir J. 2019;55(2): pii: 1901314. doi:10.1183/13993003.01314-2019.Чаулин А. М., Дупляков Д. В. Повышение кардиальных тропонинов, не ассоциированное с острым коронарным синдромом. Часть 1. Кардиология: новости, мнения, обучение. 2019;7(2):13-23. doi:10.24411/2309-1908-2019-12002.Chaulin AM, Duplyakov DV. Increased cardiac troponins, not associated with acute coronary syndrome. Part 1. Cardiology: News, Opinions, Training. 2019;7(2):13-23. (In Russ.)Чаулин А. М., Свечков Н. А., Волкова С.Л., Григорьева Ю. В. Диагностическая ценность сердечных тропонинов у пожилых пациентов, не страдающих инфарктом миокарда. Современные проблемы науки и образования. 2020;6. doi:10.17513/spno.30302.Chaulin AM, Svechkov NA, Volkova SL, Grigoreva YV. Diagnostic value of cardiac troponins in elderly patients without myocardial infarction. Modern problems of science and education. 2020;6. (In Russ.)Vanfleteren LE, Spruit MA, Wouters EF, et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016;4(11):911-24. doi:10.1016/S2213-2600(16)00097-7.Vanfleteren LE, Spruit MA, Wouters EF, et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016;4(11):911-24. doi:10.1016/S2213-2600(16)00097-7.Halpin DM, Dahl R, Hallmann C, et al. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:239-59. doi:10.2147/COPD.S75146.Halpin DM, Dahl R, Hallmann C, et al. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:239-59. doi:10.2147/COPD.S75146.Donohue JF, Hanania NA, Make B, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014;146(6):1531-42. doi:10.1378/chest.14-0117.Donohue JF, Hanania NA, Make B, et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014;146(6):1531-42. doi:10.1378/chest.14-0117.Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48-56. doi:10.1136/thoraxjnl-2012-201926.Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48-56. doi:10.1136/thoraxjnl-2012-201926.Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380-90. doi:10.7326/0003-4819-149-6-200809160-00004.Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380-90. doi:10.7326/0003-4819-149-6-200809160-00004.Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-50. doi:10.1001/jama.300.12.1439.Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-50. doi:10.1001/jama.300.12.1439.Тарзиманова А.И., Подзолков В.И. Современные принципы лечения наджелудочковых тахикардий. Кардиоваскулярная терапия и профилактика. 2020;19(5):2694. doi:10.15829/1728-8800-2020-2694.Tarzimanova AI, Podzolkov VI. Modern treatment of supraventricular tachycardia. Cardiovascular Therapy and Prevention. 2020;19(5):2694. (In Russ.)Шугушев Х. Х., Гурижева М. В., Василенко В. М. Влияние бронхолитической терапии на желудочковые нарушения ритма у больных хронической обструктивной болезнью легких. Рациональная фармакотерапия в кардиологии. 2009;5:63-6.Shugushev KhKh, Gurizheva MV, Vasilenko VM. Influence of broncholytic therapy on ventricular rhythm disorders in patients with chronic obstructive pulmonary disease. Rational Pharmacother. Card. 2009;5:63-6. (In Russ.)Lahousse L, Verhamme KM, Stricker BH, Brusselle GG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):149-64. doi:10.1016/S2213-2600(15)00518-4.Lahousse L, Verhamme KM, Stricker BH, Brusselle GG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):149-64. doi:10.1016/S2213-2600(15)00518-4.

The authors declare that there are no conflicts of interest present.